Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2003
10/16/2003US20030195168 Comprises macrocyclic diterpene compounds from Euphorbiaceae for treatment and prophylaxis of protein kinase C (PKC) related conditions (alcoholism, Alzheimer's disease, asthma, atherosclerosis); expression inhibition; computer programs
10/16/2003US20030195167 Administering lovastain for treament of autoimmune diseases (rheumatoid arthritis)
10/16/2003US20030195165 Comprises arginine as nitric oxide donor; synergistic; contains no adenosine and/or linsidomine
10/16/2003US20030195164 Novel ribozyme and its use
10/16/2003US20030195161 Composition comprising camptothecin or a camptothecin derivative and a topoisomerase II inhibitor for the treatment of cancer
10/16/2003US20030195160 Sodium channel blockers
10/16/2003US20030195158 Peptide derivatives
10/16/2003US20030195153 Comprises metalloproteinase (stromelysin) inhibitors
10/16/2003US20030195152 Polymeric conjugates of antitumor agents
10/16/2003US20030195148 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030195146 Prepared by culturing Beauveria in medium; substances thus obtained are less toxic, specifically inhibit acyl-Coenzyme A: cholesterol acyltransferase, and inhibit formation of oil droplets in macrophages
10/16/2003US20030195145 Methods of treatment with combinations of statin and aryl-substituted propanolamine derivatives
10/16/2003US20030195140 Methods and compositions for improving sleep
10/16/2003US20030195139 For treating subject with abstinence syndrome due to nicotine, an opiate, cocaine, an amphetamine, a benzodiazipine and ethanol
10/16/2003US20030195138 BAP-1: methods of assaying for cell-cycle modulators
10/16/2003US20030195131 Formed by reaction between a poly(2-propenal, 2-propenoic acid) and an organic compound containing hydroxyl groups to form protected carbonyl groups
10/16/2003US20030194806 Synthetic media for blood components
10/16/2003US20030194800 For immunization, generation of packaging cell lines, and production of immunogenic compositions
10/16/2003US20030194787 Fermentative preparation process for and crystal forms of cytostatics
10/16/2003US20030194751 Method for identifying modulators of ion channels
10/16/2003US20030194750 For inhibiting glycogen synthase kinase 3 (GSK3) in non-neoplastic conditions, via increasing protein kinase G (PKG) activity and inhibiting cGMP phosphodiesterase (PDE)
10/16/2003US20030194749 Wortmannin derivatives as probes of cellular proteins and processes
10/16/2003US20030194746 For diagnosis, prognosis, prophylaxis
10/16/2003US20030194744 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194732 For treating neoplastic diseases by testing responsiveness to interferons
10/16/2003US20030194693 Method of prevention of lysosomal leakage in eukaryotic cells by using 6-methyluracil based water-soluble compounds and method of producing thereof
10/16/2003US20030194478 Improved hunt or search performance of sport and task animals, such as hunting dogs and search dogs, by orally administering eicosapentaenoic acid and/or docosahexaenoic acid
10/16/2003US20030194453 Dietary supplement
10/16/2003US20030194449 Medicinal herbal extract carpediol for treating depression
10/16/2003US20030194448 Oral rehydration composition
10/16/2003US20030194447 Antiseptic compositions and methods
10/16/2003US20030194446 Zinc oxide compositions for dermatheraputics
10/16/2003US20030194444 Methods of treating skin and integument conditions
10/16/2003US20030194442 Insoluble drug particle compositions with improved fasted-fed effects
10/16/2003US20030194441 Antibacterial aqueous solutioncomprises: methylcellulose; citric acid; polyethylene glycol and an active drug component, especially a quinolone antibiotic; viscosity of 12 mPa.s or below at 20 degrees C.
10/16/2003US20030194440 Pharmaceutical composition for sustained release of the hmg-coa reductase inhibitor fluvastatin
10/16/2003US20030194439 Pharmaceutical dosage form for pulsatile delivery of methylphenidate
10/16/2003US20030194438 Ionically bound to hyaluronic acid, poly-gamma-glutamic acid or other ionic polymers, utilizing counter-ions of different valences to control the rate of release into the body.
10/16/2003US20030194437 Levothyroxine compositions having unique triiodothyronine Cmax properties
10/16/2003US20030194436 Levothyroxine salt and a pharmaceutically acceptable carrier.
10/16/2003US20030194432 Methods for treating multiple sclerosis employing desmethylselegiline
10/16/2003US20030194422 Methods of administering levothyroxine pharmaceutical compositions
10/16/2003US20030194421 Treatment of uveitis
10/16/2003US20030194414 Replikin peptides and antibodies therefore
10/16/2003US20030194413 Methods and compositions employing red rice fermentation products
10/16/2003US20030194409 Conjugate heat shock protein-binding peptides
10/16/2003US20030194406 P-cadherin as a target for anti-cancer therapy
10/16/2003US20030194397 Introducing platelet-rich plasma into and around the site of the injury
10/16/2003US20030194390 Alkyl cyanoacrylate and inhibitor and aggregate structure formed; alkyl fatty ester, opacifier; ablating tissue by blocking blood flow
10/16/2003US20030194389 Occlusive composition
10/16/2003US20030194385 Pharmaceutical formulations containing solubilized hydroquinone, salicylic acid and hydrocortisone for the treatment of melasma and related dermatological problems
10/16/2003US20030194378 Novel aerosol formulation containing a polar fluorinated molecule
10/16/2003US20030194375 Anti-epileptogenic agents
10/16/2003US20030192540 Therapeutic dry powder preparation
10/16/2003US20030192533 New method
10/16/2003US20030192226 Animal decoy
10/16/2003CA2708900A1 Pharmaceutical preparation containing oxycodone and naloxone
10/16/2003CA2694410A1 Pyridinoylpiperidines as 5-ht1f agonists
10/16/2003CA2513149A1 A human ribonucleotide reductase m2 subunit
10/16/2003CA2486480A1 Improved kavalactone profile
10/16/2003CA2483769A1 Identification and characterization of an anthocyanin mutant (ant1) in tomato
10/16/2003CA2482253A1 Vitamin combination for providing protection during the chemotherapy and/or radiotherapy of malignant tumours
10/16/2003CA2481995A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003CA2481976A1 Novel thyroid receptor ligands
10/16/2003CA2481970A1 Neurotrophic factor production accelerator
10/16/2003CA2481916A1 A therapeutic agent for impaired gastric accommodation
10/16/2003CA2481888A1 Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers
10/16/2003CA2481879A1 Hydroxamic acid derivatives
10/16/2003CA2481850A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003CA2481817A1 Acyl-4-carboxyphenylurea derivatives, method for production and use thereof
10/16/2003CA2481706A1 Antidiabetic agents
10/16/2003CA2481701A1 Benzoxazinone-derived compounds, their preparation and use as medicaments
10/16/2003CA2481514A1 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003CA2481463A1 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the production thereof
10/16/2003CA2481392A1 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003CA2481379A1 Medicinal composition comprising acat inhibitor and insuline resistance improving agent
10/16/2003CA2481377A1 Antihistamine-decongestant pharmaceutical compositions
10/16/2003CA2481310A1 Step-down estrogen therapy
10/16/2003CA2481309A1 Method of hormonal therapy
10/16/2003CA2481090A1 Novel pancortin-pablo protein interactions and methods of use thereof
10/16/2003CA2481035A1 (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
10/16/2003CA2481028A1 Hormone replacement therapy
10/16/2003CA2481026A1 N-`4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
10/16/2003CA2481025A1 Palatable chewable tablet
10/16/2003CA2480824A1 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
10/16/2003CA2480818A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003CA2480709A1 Method of improving absorption of vitamin e by a pet animal
10/16/2003CA2480697A1 Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases
10/16/2003CA2480579A1 Embolization
10/16/2003CA2480482A1 Synthesis of piperidine and piperazine compounds as ccr5 antagonists
10/16/2003CA2480446A1 Method and dietary composition for improving lipid digestibility
10/16/2003CA2480311A1 Oligomeric compounds for the modulation of hif-1alpha expression
10/16/2003CA2480225A1 Methods for treating rosacea with pyridones
10/16/2003CA2480194A1 Inhibitors of the s100-p53 protein-protein interaction and method of inhibiting cancer employing the same
10/16/2003CA2480084A1 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003CA2480082A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003CA2479810A1 Polymeric acyl derivatives of indoles
10/16/2003CA2479777A1 6-(4-substituted-anilino)pyrimidine derivatives, method for the preparation thereof and antiviral pharmaceutical composition comprising the same
10/16/2003CA2479522A1 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
10/16/2003CA2479520A1 P38 kinase inhibitors for treating mucus hypersecretion_
1 ... 5309 5310 5311 5312 5313 5314 5315 5316 5317 5318 5319 5320 5321 5322 5323 5324 5325 5326 5327 5328 5329 ... 7860